Vimentin and tumor-stroma ratio for neoadjuvant chemoradiotherapy response prediction in locally advanced rectal cancer.

Cancer Sci · 2023 · PMC9899599 · PMID 36221784

Europe PMC DOI

hedged sentence

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

a clear trendp = 0.062so close (0.05 < p ≤ 0.1)

Although both vimentin and TSR were no longer significant, there was still a clear trend with a 2.6 (1/0.377) lower odds of pCR if patients had vimentin‐high tumors (OR 0.377, 95% CI 0.130–1.027, p = 0.062) and a 2.9 higher odds if patients had TSR‐high tumors (OR 2.910, 95% CI 0.976–9.995, p = 0.067).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.